Previous close | 17.14 |
Open | 17.30 |
Bid | 17.35 x 300 |
Ask | 17.38 x 300 |
Day's range | 17.20 - 17.80 |
52-week range | 16.96 - 48.25 |
Volume | |
Avg. volume | 1,579,859 |
Market cap | 1.47B |
Beta (5Y monthly) | 2.16 |
PE ratio (TTM) | 7.55 |
EPS (TTM) | 2.30 |
Earnings date | 02 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 27.60 |
InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, responded to the recent petition to the U.S. Patent & Trademark Office filed by BTL Industries, Inc., in which BTL asks the USPTO to conduct an Inter Partes Review of InMode's U.S. Patent No. 8,961,511. Six months before BTL's petition, InMode sued BTL in the United States District Court for the Central District of California alleging that BTL's UltraFemme 360 and EmFemme 360 non-invasive, radio-frequency b
InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter of 2024 before the Nasdaq market opens on Thursday, May 2, 2024.
In the most recent trading session, InMode (INMD) closed at $20.62, indicating a +0.05% shift from the previous trading day.